Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
08:00am, Wednesday, 08'th Feb 2023
WESTLAKE VILLAGE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-der
Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study
12:02pm, Wednesday, 16'th Nov 2022
Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Call Transcript
02:36am, Monday, 14'th Nov 2022
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kennet
Arcutis to Present at Upcoming Investor Conference
08:00am, Friday, 11'th Nov 2022
WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-der
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates
06:48pm, Tuesday, 08'th Nov 2022
Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo
Arcutis to Report Third Quarter Financial Results
04:05pm, Tuesday, 25'th Oct 2022
WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-der
Arcutis Biotherapeutics: Keeping A Close Eye On Initial Launch Metrics For Zoryve
05:05am, Thursday, 29'th Sep 2022
Arcutis Biotherapeutics shares are down 15% year to date. Approval of Zoryve topical cream in plaque psoriasis with reasonable price point provides a degree of derisking.
Arcutis Biotherapeutics: A Name To Accumulate
11:07am, Sunday, 18'th Sep 2022
Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. fell 16% the day after receiving its first FDA approval for ZORYVE (roflumilast) in the treatment of plaque psoriasis. The market seemed t
Arcutis Biotherapeutics: Roflumilast May Be A Pipeline In A Molecule
07:41am, Monday, 12'th Sep 2022
Zoryve (roflumilast cream) was approved by the FDA to treat psoriasis on August 1, 2022. The phase 3 STRATUM trial met the endpoint and an NDA will be submitted to FDA for roflumilast foam to be appro
Arcutis to Present at Upcoming Investor Conference
08:00am, Thursday, 01'st Sep 2022
WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-de
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
12:03pm, Monday, 29'th Aug 2022
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in imm
Arcutis: Roflumilast Has Excellent Data And High Probability Of FDA Approval
05:01pm, Tuesday, 05'th Apr 2022
Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psoriasis.
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
11:30am, Friday, 25'th Mar 2022 GlobeNewswire Inc.
WESTLAKE VILLAGE, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in i
